Close
Company Search
Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Grant of LTIP Options and PDMR Dealing

6th Dec 2022 16:03

RNS Number : 8052I
Arecor Therapeutics PLC
06 December 2022
 

Arecor Therapeutics plc

("Arecor", the "Company" or the "Group")

 

Grant of LTIP Options and PDMR Dealing

 

Cambridge, UK, 6 December 2022: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, announces that on 5 December 2022, it granted a total of 270,000 options under the Company's Long Term Incentive Plan ("LTIP Options") over new ordinary shares of 1p each in the Company ("Ordinary Shares").

The LTIP Options have an exercise price of 1p and are granted to Senior Management (persons discharging managerial responsibilities ("PDMRs") of the Company. Performance conditions include commercial objectives and Total Shareholder Return during the three-year performance period.

The LTIP Options are subject to continued service and the extent to which the performance conditions are satisfied. Vested LTIP Options will normally be exercisable until the tenth anniversary of the grant date, after which time they will lapse. They are subject to a condition that the LTIP Options or the Ordinary Shares acquired on exercise of the LTIP Options (other than those sold to cover tax and National Insurance) are held for a minimum one-year period from vesting.

The notifications below, made in accordance with the requirements of the Market Abuse Regulation, provide further detail.

 

For further information, please contact:

 

Arecor Therapeutics plc

 

www.arecor.com

Dr Sarah Howell, Chief Executive Officer

Tel: +44 (0) 1223 426060

Email: [email protected]

 

Susan Lowther, Chief Financial Officer

Tel: +44 (0) 1223 426060

Email: [email protected]

 

 

Mo Noonan, Communications

Tel: +44 (0) 7876 444977

Email: [email protected]

 

Panmure Gordon (UK) Limited

(NOMAD and Broker)

Freddy Crossley, Emma Earl (Corporate Finance)

Rupert Dearden (Corporate Broking)

 

Tel: +44 (0) 20 7886 2500

 

 

Consilium Strategic Communications

Chris Gardner, David Daley, Angela Gray

Tel: +44 (0) 20 3709 5700

Email: [email protected]

 

Notes to Editors

 

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary formulation technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat ™ platform is supported by an extensive patent portfolio. 

 

For further details please see our website, www.arecor.com

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

 

Details of the person discharging managerial responsibilities/person closely associated

a)

Name:

Shafiq Choudhary

2. 

Reason for the notification

a)

Position/status:

Managing Director, Tetris Pharma Ltd

b)

Initial notification/Amendment:

Initial notification

3. 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:

Arecor Therapeutics plc

b)

LEI:

98450093D12I3A8DDD58

4. 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument:

Identification code:

Ordinary shares of 1 pence each

GB00BMWLM973

b)

Nature of the transaction:

Grant of options over ordinary shares

c)

Price(s) and volume(s):

 

Exercise Price(s)

Volume(s)

0.01

50,000

 

 

d)

Aggregated information:

· Aggregated volume:

· Price:

 

50,000

N/A

e)

Date of the transaction:

5 December 2022

f)

Place of the transaction:

Outside of a trading venue

 

 

 

 Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

 

Details of the person discharging managerial responsibilities/person closely associated

a)

Name:

David Gerring

2. 

Reason for the notification

a)

Position/status:

VP Development

b)

Initial notification/Amendment:

Initial notification

3. 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:

Arecor Therapeutics plc

b)

LEI:

98450093D12I3A8DDD58

4. 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument:

Identification code:

Ordinary shares of 1 pence each

GB00BMWLM973

b)

Nature of the transaction:

Grant of options over ordinary shares

c)

Price(s) and volume(s):

 

Exercise Price(s)

Volume(s)

0.01

20,000

 

 

d)

Aggregated information:

· Aggregated volume:

· Price:

 

20,000

N/A

e)

Date of the transaction:

5 December 2022

f)

Place of the transaction:

Outside of a trading venue

 

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

 

Details of the person discharging managerial responsibilities/person closely associated

a)

Name:

Sarah Howell

2. 

Reason for the notification

a)

Position/status:

Chief Executive Officer

b)

Initial notification/Amendment:

Initial notification

3. 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:

Arecor Therapeutics plc

b)

LEI:

98450093D12I3A8DDD58

4. 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument:

Identification code:

Ordinary shares of 1 pence each

GB00BMWLM973

b)

Nature of the transaction:

Grant of options over ordinary shares

c)

Price(s) and volume(s):

 

Exercise Price(s)

Volume(s)

0.01

80,000

 

 

d)

Aggregated information:

· Aggregated volume:

· Price:

 

80,000

N/A

e)

Date of the transaction:

5 December 2022

f)

Place of the transaction:

Outside of a trading venue

 

 

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

 

Details of the person discharging managerial responsibilities/person closely associated

a)

Name:

Jane Jezek

2. 

Reason for the notification

a)

Position/status:

Chief Scientific Officer

b)

Initial notification/Amendment:

Initial notification

3. 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:

Arecor Therapeutics plc

b)

LEI:

98450093D12I3A8DDD58

4. 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument:

Identification code:

Ordinary shares of 1 pence each

GB00BMWLM973

b)

Nature of the transaction:

Grant of options over ordinary shares

c)

Price(s) and volume(s):

 

Exercise Price(s)

Volume(s)

0.01

40,000

 

 

d)

Aggregated information:

· Aggregated volume:

· Price:

 

40,000

N/A

e)

Date of the transaction:

5 December 2022

f)

Place of the transaction:

Outside of a trading venue

 

 

 

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

 

Details of the person discharging managerial responsibilities/person closely associated

a)

Name:

Fiona Lawrence

2. 

Reason for the notification

a)

Position/status:

VP Clinical & Regulatory Affairs and QA

b)

Initial notification/Amendment:

Initial notification

3. 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:

Arecor Therapeutics plc

b)

LEI:

98450093D12I3A8DDD58

4. 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument:

Identification code:

Ordinary shares of 1 pence each

GB00BMWLM973

b)

Nature of the transaction:

Grant of options over ordinary shares

c)

Price(s) and volume(s):

 

Exercise Price(s)

Volume(s)

0.01

16,667

 

 

d)

Aggregated information:

· Aggregated volume:

· Price:

 

16,667

N/A

e)

Date of the transaction:

5 December 2022

f)

Place of the transaction:

Outside of a trading venue

 

 

 

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

 

Details of the person discharging managerial responsibilities/person closely associated

a)

Name:

Susan Lowther

2. 

Reason for the notification

a)

Position/status:

Chief Financial Officer

b)

Initial notification/Amendment:

Initial notification

3. 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:

Arecor Therapeutics plc

b)

LEI:

98450093D12I3A8DDD58

4. 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument:

Identification code:

Ordinary shares of 1 pence each

GB00BMWLM973

b)

Nature of the transaction:

Grant of options over ordinary shares

c)

Price(s) and volume(s):

 

Exercise Price(s)

Volume(s)

0.01

63,333

 

 

d)

Aggregated information:

· Aggregated volume:

· Price:

 

63,333

N/A

e)

Date of the transaction:

5 December 2022

f)

Place of the transaction:

Outside of a trading venue

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHUPGGUPUPPGQQ

Related Shares:

Arecor Therape
FTSE 100 Latest
Value8,474.74
Change-133.74